Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone ...
As an aside, in the tech space, see What’s Happening With Snap Stock? Although the recent Amgen update didn’t bode well with ...
A hidden tab in an Excel spreadsheet published nine months ago has wiped $12 billion off Amgen’s market cap. The tab ...
Amgen Inc.'s stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its ...
On Tuesday, a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value.
Recent health news highlights include Amgen addressing bone density concerns, AstraZeneca revising its financial outlook ...
(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone ...
Wednesday said there is no association between administration of experimental weight loss drug MariTide and changes ...
Amgen shares dropped over 7% Tuesday after bone density data from an early-stage trial of its weight loss drug, MariTide, ...